PMC6387706_01
Axial noncontrast CT (a) shows a small calcification at the tail of the pancreas. Axial arterial phase CT (b) shows a 2.5 cm hyperenhancing pancreatic mass which on venous phase ((c) and (d)) shows slightly more heterogeneity compared to the spleen. Endoscopic ultrasound (e) showed heterogeneous hypoechoic 1.7 x 2.5 cm pancreatic tail mass with calcifications.
CRIE2019-6809479.001.jpg
PMC6387706_01_CRIE2019-6809479.001.jpg
fig1
CT (Figure 1) showed a solid, hyperenhancing 2.5cm pancreatic tail mass with slow washout. 111In-pentetreotide (Octreoscan) study (Figure 2) demonstrated absence of radiotracer uptake ruling out a splenule. CT guided fine needle biopsy of the mass confirmed neuroendocrine etiology.
24-hour 111In-pentetreotide scan. Anterior whole body planar image (a), MIP reconstruction of SPECT acquisition (b), axial SPECT image (c), and fused axial SPECT/CT image (d) show normal biodistribution of the radiotracer and no uptake in the pancreatic tail mass, ruling out a splenule.
CRIE2019-6809479.002.jpg
PMC6387706_01_CRIE2019-6809479.002.jpg
fig2
CT (Figure 1) showed a solid, hyperenhancing 2.5cm pancreatic tail mass with slow washout. 111In-pentetreotide (Octreoscan) study (Figure 2) demonstrated absence of radiotracer uptake ruling out a splenule. CT guided fine needle biopsy of the mass confirmed neuroendocrine etiology.